Drugs & Targets FDA approves FoundationOne CDx as a Companion Diagnostic for Piqray in new indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda in NMIBC indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA accepts NDA for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements December 06, 2019Vol.45 No.45
Drugs & Targets China approves Keytruda for first-line treatment in metastatic squamous NSCLC+chemo indication December 06, 2019Vol.45 No.45
Drugs & Targets Lynparza approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA takes second action under international collaboration, approving treatment option for CLL or SLL November 22, 2019Vol.45 No.44
Drugs & Targets FDA grants Q BioMed approval to manufacture non-opioid cancer palliation drug November 22, 2019Vol.45 No.44
Drugs & Targets FDA approves crizanlizumab-tmca for sickle cell disease November 22, 2019Vol.45 No.44
Drugs & Targets European Commission approves two regimens of Keytruda for front-line metastatic, unresectable HNSCC November 22, 2019Vol.45 No.44
